Benign Prostatic Hyperplasia
Updated Treatment and Prevention Management
DOI:
https://doi.org/10.53366/jimki.v8i3.230Keywords:
Benign prostatic hyperplasia, management, prevention, treatmentAbstract
Background: Benign prostatic hyperplasia (BPH) is a histologic diagnosis which referred to a proliferation of ephitelial and smooth muscle tissues in the transitional zone of the prostate. BPH affects roughly 18-25% of all male aged 40 years and above and 90% of all male aged beyond 80. BPH is known to be able to significantly decrease quality of life and hence people with BPH need treatments to help them alleviate its effects.
Methods: The research was conducted using literature review from the most actual and respected clinical guidelines, scientific literatures, websites, and textbooks on BPH.
Discussion: There are three main groups of treatment, which are conservative, pharmacological, and surgical treatments. Treatment should be chosen from the least invasive first with the aim of increasing quality of life. Even if it is hard to prevent, several preventive measures could be conducted, such as limiting usage of BPH-inducing drugs, doing healthy lifestyle which involves no smoking, active exercise, body weight control, and balanced diet.
Conclusion: BPH is a very prevalent condition on elderly male population. Even though it is not deadly, a proper treatment management need to be done by virtue of its ability to significantly decrease quality of life.
References
1. McVary K, Roehrborn C. Management of benign prostatic hyperplasia [Internet]. American Urological Associaton. 2014 [cited 2020 Aug 28]. Available from: https://www.auanet.org/benign-prostatic-hyperplasia
2. Egan KB. The Epidemiology of Benign Prostatic Hyperplasia Associated with Lower Urinary Tract Symptoms: Prevalence and Incident Rates. Urol Clin North Am. 2016 Aug;43(3):289–97.
3. Scher H, Eastham J. Benign and malignant diseases of the prostate. In: Harrison’s principles of internal medicine. 20th ed. New York: McGraw Hill Education; 2018. p. 623–32.
4. Mochtar C, Umbas R, Soebadi D, Rasyid N, Noegroho B, Poernomo BB, et al. Panduan penatalaksanaan klinis pembesaran prostat jinak (benign prostatyic hyperplasia/BPH). 2nd ed. Jakarta: Ikatan Ahli Urologi Indonesia; 2015. 12–25 p.
5. Stelzner S. Intraoperative management of iris prolapse [Internet]. American academy of ophthalmology. 2019 [cited 2020 Aug 30]. Available from: http://eyewiki.aao.org/Intraoperative_Management_of_Iris_Prolapse
6. Lue T. Male sexual dysfunction. In: Smith & Tanagho’s general urology. 18th ed. New York: McGraw Hill Education; 2013. p. 600, 610.
7. Pattanaik S, Mavuduru R, Panda A, Matthew J, Agarwal M, Hwang E, et al. Phosphodiesterase inhibitors for lower urinary tract symptims consistent with benign prostatic hyperplasia. Urol Clin North Am. 2018 Nov 16;(11).
8. National Cancer Institute. TURP [Internet]. National Cancer Institute. 2011 [cited 2020 Sep 1]. Available from: https://www.cancer.gov/publications/dictionaries/cancer-terms
9. Kristal AR, Arnold KB, Schenk JM, Neuhouser ML, Goodman P, Penson DF, et al. Dietary Patterns, Supplement Use, and the Risk of Symptomatic Benign Prostatic Hyperplasia: Results from the Prostate Cancer Prevention Trial. Am J Epidemiol. 2008 Apr 15;167(8):925–34.
10. Roehrborn C. Benign prostatic hyperplasia: etiology, pathophysiology, epidemiology, and natural history. In: Campbell-Walsh urology. 11th ed. Philadelphia: Elsevier; 2016. p. 2440–4.
2. Egan KB. The Epidemiology of Benign Prostatic Hyperplasia Associated with Lower Urinary Tract Symptoms: Prevalence and Incident Rates. Urol Clin North Am. 2016 Aug;43(3):289–97.
3. Scher H, Eastham J. Benign and malignant diseases of the prostate. In: Harrison’s principles of internal medicine. 20th ed. New York: McGraw Hill Education; 2018. p. 623–32.
4. Mochtar C, Umbas R, Soebadi D, Rasyid N, Noegroho B, Poernomo BB, et al. Panduan penatalaksanaan klinis pembesaran prostat jinak (benign prostatyic hyperplasia/BPH). 2nd ed. Jakarta: Ikatan Ahli Urologi Indonesia; 2015. 12–25 p.
5. Stelzner S. Intraoperative management of iris prolapse [Internet]. American academy of ophthalmology. 2019 [cited 2020 Aug 30]. Available from: http://eyewiki.aao.org/Intraoperative_Management_of_Iris_Prolapse
6. Lue T. Male sexual dysfunction. In: Smith & Tanagho’s general urology. 18th ed. New York: McGraw Hill Education; 2013. p. 600, 610.
7. Pattanaik S, Mavuduru R, Panda A, Matthew J, Agarwal M, Hwang E, et al. Phosphodiesterase inhibitors for lower urinary tract symptims consistent with benign prostatic hyperplasia. Urol Clin North Am. 2018 Nov 16;(11).
8. National Cancer Institute. TURP [Internet]. National Cancer Institute. 2011 [cited 2020 Sep 1]. Available from: https://www.cancer.gov/publications/dictionaries/cancer-terms
9. Kristal AR, Arnold KB, Schenk JM, Neuhouser ML, Goodman P, Penson DF, et al. Dietary Patterns, Supplement Use, and the Risk of Symptomatic Benign Prostatic Hyperplasia: Results from the Prostate Cancer Prevention Trial. Am J Epidemiol. 2008 Apr 15;167(8):925–34.
10. Roehrborn C. Benign prostatic hyperplasia: etiology, pathophysiology, epidemiology, and natural history. In: Campbell-Walsh urology. 11th ed. Philadelphia: Elsevier; 2016. p. 2440–4.
Downloads
Published
2021-02-21
Issue
Section
Article Review
How to Cite
Benign Prostatic Hyperplasia: Updated Treatment and Prevention Management. (2021). JIMKI: Jurnal Ilmiah Mahasiswa Kedokteran Indonesia, 8(3), 90-97. https://doi.org/10.53366/jimki.v8i3.230
Similar Articles
- Faridah Alatas, PENATALAKSANAAN HOLISTIK DAN KOMPREHENSIF PADA BATITA DENGAN TONSILITIS KRONIS DAN RIWAYAT KEJANG DEMAM , JIMKI: Jurnal Ilmiah Mahasiswa Kedokteran Indonesia: Vol. 7 No. 1 (2019): JIMKI : Jurnal Ilmiah Mahasiswa Kedokteran Indonesia Volume 7.1 Edisi Januari - April 2019
- Mohammad Ridho Devantoro, Hydrocloroquin treatment of COVID-19, Is it correct and are there any other alternatives? , JIMKI: Jurnal Ilmiah Mahasiswa Kedokteran Indonesia: Vol. 8 No. 2 (2020): JIMKI: Jurnal Ilmiah Mahasiswa Kedokteran Indonesia Volume 8.2 Edisi Maret - Agustus 2020
- Felix Khosasi, Cut Adeya Adella, Dwi Faradina, Lokot Donna Lubis, Elbert Elbert, IN VITRO EVALUATION OF THE ANTIBACTERIAL POTENTIAL OF PSIDIUM GUAJAVA LEAF EXTRACT AGAINST ESCHERICHIA COLI: UNCOVERING THE ROLE OF PHYTOCHEMICAL COMPOUNDS. , JIMKI: Jurnal Ilmiah Mahasiswa Kedokteran Indonesia: Vol. 10 No. 3 (2024): JIMKI: Jurnal Ilmiah Mahasiswa Kedokteran Indonesia Vol. 10.3 2024
- Nabil Athoillah, Ditya Pramudyaning Tias, Ichlasul Mahdi Fardhani, Setiadi Drajad Kurniawan, TUBERCULOSIS PATTERN ON CHEST X-RAY OF A 16-YEAR-OLD FEMALE WITH DROWNING-RELATED ASPIRATION PNEUMONIA IN ENDEMIC COUNTRY, INDONESIA: A CASE REPORT , JIMKI: Jurnal Ilmiah Mahasiswa Kedokteran Indonesia: Vol. 11 No. 2 (2025): JIMKI: Jurnal Ilmiah Mahasiswa Kedokteran Indonesia Vol. 11.2 (2025)
- Theodora Agverianti, Muhartono Muhartono, Khairun Nisa Berawi, PENGARUH PEMBERIAN EKSTRAK ETANOL RIMPANG LENGKUAS (ALPINIA GALANGA) TERHADAP GAMBARAN HISTOPATOLOGI HEPAR MENCIT (MUS MUSCULUS L.) YANG DIINDUKSI MONOSODIUM GLUTAMATE , JIMKI: Jurnal Ilmiah Mahasiswa Kedokteran Indonesia: Vol. 7 No. 2 (2019): JIMKI : Jurnal Ilmiah Mahasiswa Kedokteran Indonesia Volume 7.2 Edisi Mei - Oktober 2019
- imam hermansyah, Eddy Zulfikar, CAR-T-ICI: COMBINATION OF CHIMERIC ANTIGEN RECEPTOR T-CELL WITH ANTI PD-1 IMMUNE CHECKPOINT INHIBITOR AS A NOVEL TREATMENT FOR COLORECTAL CANCER , JIMKI: Jurnal Ilmiah Mahasiswa Kedokteran Indonesia: Vol. 9 No. 1 (2021): JIMKI: Jurnal Ilmiah Mahasiswa Kedokteran Indonesia Volume 9.1 Edisi Maret - Juli 2021
- Abed Nego Okthara Sebayang, EFEK KARDIOTOKSIK OBAT KEMOTERAPI DOXORUBICIN , JIMKI: Jurnal Ilmiah Mahasiswa Kedokteran Indonesia: Vol. 7 No. 1 (2019): JIMKI : Jurnal Ilmiah Mahasiswa Kedokteran Indonesia Volume 7.1 Edisi Januari - April 2019
- Aldian Mulyanto Lokaria, Berliana Islamiyarti Hydra, Zelly Dia Rofinda, PENGUJIAN EFEKTIVITAS EKSTRAK CAPSICUM ANNUUM SEBAGAI ANTI INFLAMASI PADA TIKUS WISTAR YANG DIINDUKSI CCL4 , JIMKI: Jurnal Ilmiah Mahasiswa Kedokteran Indonesia: Vol. 6 No. 1 (2018): JIMKI : Jurnal Ilmiah Mahasiswa Kedokteran Indonesia Volume 6.1 Edisi April - September 2018
- Alfi Rahmatika, Muhammad Mufaiduddin, Innelya Innelya, The Potency of CtpF in Mycobacterium tuberculosis in The Development of CtpF-Inhibitors as Innovative Target Therapy in MDR/DR TB Treatment , JIMKI: Jurnal Ilmiah Mahasiswa Kedokteran Indonesia: Vol. 10 No. 1 (2022): JIMKI (Jurnal Ilmiah Mahasiswa Kedokteran Indonesia) Volume 10 Nomor 1 Periode Maret-September 2022
- Sanjaya Winarta, Raimond Loa, Renaldo Thosal, THE POTENTIAL OF SIRNA ENCAPSULATED BY NANOPARTICLE AS SILENCING AGENT fOR SFLT-1 AND NRF-2 , JIMKI: Jurnal Ilmiah Mahasiswa Kedokteran Indonesia: Vol. 9 No. 3 (2022): JIMKI: Jurnal Ilmiah Mahasiswa Kedokteran Indonesia Volume 9.3 Edisi Desember 2021-April 2022
You may also start an advanced similarity search for this article.